Drug manufacturer Gilead will voluntarily extend 340B pricing to critical access hospitals, sole community hospitals, and rural referral centers on Veklury (remdesivir), its injectable antiviral treatment for COVID-19, the company said late Tuesday.
The U.S. Food and Drug Administration (FDA) late last week approved Veklury for administration to outpatients with mild-to-moderate COVID-19. It previously was approved for inpatient administration only. 340B discounts apply to covered outpatient drugs only. The FDA’s decision meant that 340B pricing became available for the first time on Veklury, which is in very high demand now due to shortages of other therapies.
Drug manufacturer Gilead will voluntarily extend 340B pricing to critical access hospitals, sole community hospitals, and rural referral centers on Veklury (remdesivir), its injectable antiviral treatment for COVID-19, the company said late Tuesday.
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.